Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- Normal physiology of the GH/IGF-I axis
- Hormones of the hypothalamus and pituitary
- The GH/IGF-I axis
- Family of insulin-like growth factors
- IGFs, their receptors and their binding proteins
- Acromegaly
- Reasons for an excess of GH
- Microadenoma and macroadenoma
- Treatment of acromegaly
- GH-deficiency
- Growth failure/short stature
- GH-deficiency: growth before/after GH treatment
- GH treatment criteria of idiopathic short stature
- GH-deficiency in aging
- Metabolic effects of GH/IGF-I axis: glucose
- IGF-I treatment
- Examples of insulin resistant patients
- Type 1 diabetes
- Insulin and rhIGF-I treatment in type-1 diabetes
- Metabolic defects in type-2 diabetes
- Type 2 diabetes mellitus
- rhIGF-I effect on glycemic control
- rhIGF-I action on insulin resistance
- Metabolic effects of GH/IGF-I axis: lipids
- Metabolic effects of GH/IGF-I axis: proteins
- Non-islet cell tumor hypoglycemia
- CT-scan showing non-islet cell tumor
- Image of the tumor (hemangiopericytoma)
- Processing of insulin-like growth factor-2
- Unprocessed IGF-II can cause hypoglycemia
- Interaction of unprocessed IGF-II with IGFBP3
- Metabolic effects of ''big IGF-II''
- Summary of non-islet cell tumor hypoglycemia
- Plasma IGF-I and prostate cancer risk
- Involvement of the IGF-I receptor in cancer
- Structure of IGF-I receptor
- Results of IGF-I receptor inhibition study
- Summary
- Acknowledgements
Topics Covered
- Lack of growth hormone leads to short stature and excess leads to gigantism or acromegaly
- IGF-1 is the main mediator of these effects
- Both hormones have similar but different effects on protein, lipid and carbohydrate metabolism as well as bone development and growth
- The IGF system plays a role in cancer progression
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
LeRoith, D. (2019, December 4). The growth hormone/insulin-like growth factor-1 axis in health and disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/DFQR4306.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Derek LeRoith has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
The growth hormone/insulin-like growth factor-1 axis in health and disease
A selection of talks on Metabolism & Nutrition
Transcript
Please wait while the transcript is being prepared...
0:00
So I'm Derek LeRoith, Chief of the
Division of Endocrinology, Diabetes, and
Bone Diseases at
Mount Sinai School of Medicine.
And today, my discussion is going
to be on "The Growth Hormone and
Insulin-Like Growth Factor-1 Axis
in Health and Disease".
0:17
So in discussing growth hormone IGF-I
axis, today what we want to cover is
the normal physiology of the axis,
disorders of the growth hormone IGF axis,
including disorders like acromegaly,
growth retardation and aging.
And then finally,
we'll discuss growth hormone and
IGF-I axis in conditions such as diabetes,
tumor hypoglycemia and
in general, forms of cancer.
0:46
So let's talk firstly about
the normal physiology of
the growth hormone IGF-I axis.
0:53
This slide shows the hypothalamus and
the pituitary.
And as you can see,
there are hypothalamic-releasing and
hypothalamic inhibitory hormones,
which reach the pituitary gland and
stimulate the release of prolactin, growth
hormone, thyrotropin or TSH, luteinizing
hormone, follicular-stimulating hormone,
and corticotropin.
And there are specific cells
as shown here, the lactotroph,
the mammosomatotroph,
the thyrotroph, the gonadotroph, and
the corticotroph,
each of which release these hormones.
But the hormone that we'll be dealing
with today is growth hormone.
1:34
So this slide shows how
the growth hormone,
IGF axis works under normal
physiological conditions.
As you can see, stress, sleep,
exercise, etc affect the hypothalamus
to release the growth hormone-releasing
hormone, which reaches the anterior
pituitary to stimulate growth
hormone released to the periphery.
Once it reaches the liver, muscle,
adipose, or bone, it then stimulates
the synthesis and release of
insulin-like growth factor-1, or IGF-I,
which then reaches the circulation, and
has a positive effect on target tissues.
IGF-I, on the other hand, has a negative
feedback to the hypothalamus and
the pituitary, to inhibit growth hormone.
And this is the normal negative
feedback regulation so
well-known in the endocrine system.
Hide